English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data from  BRCA2  mutation carriers undergoing intensive combined breast screening are scarce.    Methods  We have collated the results of screening with either annual mammography or mammography with MRI in female  BRCA2  mutation carriers in Manchester and Oslo and use a Manchester control group of  BRCA2  mutation carriers who had their first breast cancer diagnosed without intensive screening.    Results  Eighty-seven  BRCA2  mutation carriers had undergone combined ( n  = 34) or mammography ( n  = 53) screening compared to 274 without such intensive screening. Ten year breast cancer specific survival was 100 % in the combined group (95 % CI 82.5–100 %) and 85.5 % (95 % CI 72.6–98.4 %) in the mammography group compared to 74.6 % (95 % CI 66.6–82.6 %) in the control group. Better survival was driven by lymph node status (negative in 67 % of screened vs 39 % of unscreened women;  p  < 0.001) and a significantly greater proportion of intensively screened women had invasive breast cancers <2 cm at diagnosis (74.6 % vs 50.4 %;  p  = 0.002).    Conclusion  Intensive combined breast cancer screening with annual MRI and mammography appears to improve survival from breast cancer in  BRCA2  mutation carriers. Data from larger groups are required to confirm the effectiveness of combined screening in  BRCA2  carriers.

Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality